Last reviewed · How we verify

Adibelimab

Second Affiliated Hospital of Xi'an Jiaotong University · Phase 2 active Small molecule

Adibelimab is a Small molecule drug developed by Second Affiliated Hospital of Xi'an Jiaotong University. It is currently in Phase 2 development. Also known as: Famitinib, Chemotherapy.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameAdibelimab
Also known asFamitinib, Chemotherapy
SponsorSecond Affiliated Hospital of Xi'an Jiaotong University
ModalitySmall molecule
Therapeutic areaOther
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Adibelimab

What is Adibelimab?

Adibelimab is a Small molecule drug developed by Second Affiliated Hospital of Xi'an Jiaotong University.

Who makes Adibelimab?

Adibelimab is developed by Second Affiliated Hospital of Xi'an Jiaotong University (see full Second Affiliated Hospital of Xi'an Jiaotong University pipeline at /company/second-affiliated-hospital-of-xi-an-jiaotong-university).

Is Adibelimab also known as anything else?

Adibelimab is also known as Famitinib, Chemotherapy.

What development phase is Adibelimab in?

Adibelimab is in Phase 2.

Related